tradingkey.logo
tradingkey.logo
Search

Intellia Therapeutics Says One Dose Of NEX-Z Shows Durable TTR Reductions Of At Least 90% Through Three Years

ReutersSep 25, 2025 3:27 PM
facebooktwitterlinkedin
View all comments0

- Intellia Therapeutics Inc NTLA.O:

  • INTELLIA THERAPEUTICS ANNOUNCES POSITIVE LONGER-TERM PHASE 1 DATA FOR NEXIGURAN ZICLUMERAN (NEX-Z) IN PATIENTS WITH HEREDITARY TRANSTHYRETIN (ATTR) AMYLOIDOSIS WITH POLYNEUROPATHY

  • INTELLIA THERAPEUTICS INC - ONE DOSE OF NEX-Z SHOWS DURABLE TTR REDUCTIONS OF AT LEAST 90% THROUGH THREE YEARS

  • INTELLIA THERAPEUTICS INC - FAVORABLE SAFETY DATA WITH NO NEW DRUG-RELATED EVENTS

  • INTELLIA THERAPEUTICS INC - PHASE 3 MAGNITUDE-2 TRIAL ENROLLMENT EXPECTED BY FIRST HALF 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI